Remedy Plan Therapeutics has commenced dosing in a randomised Phase I trial of hyperbolic NAMPT inhibitor, RPT1G, for cancers.

PBGENE-HBV specifically targets the hepatitis B viral genome. Credit: Jarun Ontakrai/Shutterstock. Precision Biosciences has gained the approval of its clinical trial application (CTA) in Hong Kong to ...

Immunocore has dosed the first subject in the Phase I/II trial of IMC-R117C for treating colorectal and other gastrointestinal cancers.

Tenya Therapeutics has said that its treatment for the heart condition was generally well tolerated despite some mild adverse events.

AbbVie announced positive topline results from its pivotal Phase III TEMPO-2 trial, evaluating tavapadon as a flexible-dose (5mg to 15mg, once daily) monotherapy in early Parkinson's disease (PD).

HighField has received clearance for its IND application from the CDE of China's NMPA to commence the Phase I trial of HF50.

The Phase II Orchestra trial ended meeting none of its endpoints as the company announces plans to pivot from the drug in favour of others.

Sanofi and Teva Pharmaceuticals have reported that the Phase IIb RELIEVE UCCD study of the human IgG1-λ2 monoclonal antibody targeting TL1A, duvakitug, met its primary endpoints in patients with ...

CEPI has announced that it will fund a vaccine safety project in Africa. Credit: Anadolu / Getty images. The Coalition for Epidemic Preparedness Innovations (CEPI) has announced that it is providing ...

The trial of the company’s metastatic pancreatic cancer treatment, elraglusib, similarly saw the one-year survival rate reach 43.6%.

The company’s chronic thyroid eye disease treatment, veligrotug, was able to reduce eye bulge by 56% compared with placebo.

Corcept Therapeutics has reported positive outcomes from its Phase III study of relacorilant, a treatment for endogenous hypercortisolism.